首页
小分子和化合物库
按“信号通路”分类
JAK/STAT 信号通路
EGFR
Trastuzumab emtansine (anti-ERBB2), 受体蛋白酪氨酸激酶 erbB-2 抑制剂

Trastuzumab emtansine (anti-ERBB2), 受体蛋白酪氨酸激酶 erbB-2 抑制剂

级别和纯度:

≥90%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human)
亚型: Human IgG1
偶联: SMCC-DM1

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab175686-100μg	100μg	现货
Ab175686-1mg	1mg	现货
Ab175686-5mg	5mg	现货
Ab175686-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: ERBB2

Accession#:P04626 (14) CD340 (7) ERBB2 (14) Gene ID:2064 (14) HER2 (12) Receptor Tyrosine Kinase (2808) SMCC-DM1 (2)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Trastuzumab emtansine (anti-ERBB2), 受体蛋白酪氨酸激酶 erbB-2 抑制剂
别名	ado-trastuzumab emtansine \| Kadcyla,PRO-132365 \| RG-3502 \| 曲妥珠单抗-美坦新偶联物 \| ERBB2抗体 \| ERBB2单克隆抗体 \| ERBB2药靶抗体
英文别名	Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody \| C erb B2/neu protein antibody \| CD340 antibody \| CD340 antigen antibody \| Cerb B2/neu protein antibody \| CerbB2 antibody \| Erb b2 receptor tyr
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	ERBB2
种属反应性	人(Human)
偶联	SMCC-DM1
作用类型	抑制剂
作用机制	受体蛋白酪氨酸激酶 erbB-2 抑制剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	145 kDa
纯化方法	Protein A purified
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1018448-65-1
分子类型	抗体偶联药物

关联靶点（人）

ERBB2 Tclin 受体酪氨酸蛋白激酶 erbB-2(Receptor tyrosine-protein kinase erbB-2) (0 活性数据)

点击查看靶蛋白信息： ERBB2

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 活性数据)

点击查看靶蛋白信息： ERBB2

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ERBB2 Tclin Epidermal growth factor receptor and ErbB2 (HER1 and HER2) (186 活性数据)

点击查看靶蛋白信息： ERBB2

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ERBB2 Tclin Epidermal growth factor receptor (487 活性数据)

点击查看靶蛋白信息： ERBB2

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

ERBB2 Tclin FASN/HER2 (2 活性数据)

点击查看靶蛋白信息： ERBB2

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Trastuzumab emtansine (anti-ERBB2) (Ab175686)

Trastuzumab emtansine (anti-ERBB2) (Ab175686) - Flow Cytometry
Flow Cytometry analysis of MCF7 cells labelling ERBB2 (red) with Trastuzumab emtansine (anti-ERBB2) (Ab175686) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

ELISA: Trastuzumab emtansine (anti-ERBB2) (Ab175686)

Trastuzumab emtansine (anti-ERBB2) (Ab175686) - ELISA
Immobilized Recombinant Human ErbB2/HER2 protein (rp169607) at 1.0 μg/mL can bind Trastuzumab emtansine (anti-ERBB2) (Ab175686) with the EC₅₀ of 138.5 ng/mL.

SEC: Trastuzumab emtansine (anti-ERBB2) (Ab175686)

Trastuzumab emtansine (anti-ERBB2) (Ab175686) - SEC
The purity of Trastuzumab emtansine (anti-ERBB2) (Ab175686) is more than 95% verified by HPLC.

SEC-MS: Trastuzumab emtansine (anti-ERBB2) (Ab175686)

Trastuzumab emtansine (anti-ERBB2) (Ab175686) - SEC-MS
The drug-to-antibody ratio (DAR) of the Trastuzumab emtansine (anti-ERBB2) (Ab175686) is 3.3.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ25F0521284	分析证书	Ab175686
ZJ25F0521283	分析证书	Ab175686
ZJ25F0521282	分析证书	Ab175686

技术文档和文章

抗体偶联药物ADC：精确制导，爆破癌症

Categories: 技术文章

探索主题:

抗体偶联药物单克隆抗体肿瘤偶联 ADC 癌症

Antibody-coupled drug ADCs: Precise guidance, cancer destruction

Categories: 技术文章

探索主题:

Antibody conjugated drugs Tumors Conjugated ADC Monoclonal antibodies Cancer

引用文献

1. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ et al.. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.. Cancer Res, 68 (22): (9280-90). [PMID:19010901]
2. Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E et al.. (2014) Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.. Mol Cancer Ther, 13 (11): (2618-29). [PMID:25189543]
3. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. (2019) The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.. Chem Pharm Bull, 67 (3): (173-185). [PMID:30827997]
4. Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE et al.. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.. Lancet Oncol, 20 (8): (1124-1135). [PMID:31257177]
5. Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J et al.. (2019) Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).. Eur J Med Chem, 183 (111682). [PMID:31563805]
6. Nadal-Serrano M, Morancho B, Escrivá-de-Romaní S, Morales CB, Luque A, Escorihuela M, Espinosa Bravo M, Peg V, Dijcks FA, Dokter WHA et al.. (2020) The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.. Cancers (Basel), 12 (3): (670). [PMID:32183023]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度